Omalizumab Treated Urticaria Patients Display T Cell and Thrombocyte‐Associated Gene Regulation
ABSTRACT Background Chronic spontaneous urticaria (CSU) is a debilitating inflammatory skin disease with a prevalence of approximately 1% of the population. It is characterized by recurrent itchy wheals and/or angioedema for more than 6 weeks without known triggers leading to a high quality of life...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-02-01
|
| Series: | Immunity, Inflammation and Disease |
| Online Access: | https://doi.org/10.1002/iid3.70132 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849765377416888320 |
|---|---|
| author | Anna Smola Heike C. Hawerkamp Péter Oláh Andreas Kislat Nicole Duschner Bernhard Homey Stephan Meller |
| author_facet | Anna Smola Heike C. Hawerkamp Péter Oláh Andreas Kislat Nicole Duschner Bernhard Homey Stephan Meller |
| author_sort | Anna Smola |
| collection | DOAJ |
| description | ABSTRACT Background Chronic spontaneous urticaria (CSU) is a debilitating inflammatory skin disease with a prevalence of approximately 1% of the population. It is characterized by recurrent itchy wheals and/or angioedema for more than 6 weeks without known triggers leading to a high quality of life impairment. The pathogenesis of CSU remains not fully understood. Objective This study aimed to explore the pathomechanism of CSU beyond mast cells and IgE‐dependent histamine release and to identify possible biomarkers for the disease and its treatment. Methods We investigated a patient cohort in the first month of omalizumab treatment regarding the IgE levels and changes in gene and miRNA expression in peripheral blood. The cohort was divided into responders and nonresponders (depending on the score of the urticaria control test) and compared to a group of healthy controls. Results Our messenger RNA and microRNA microarray analyses revealed the greatest changes in expression levels on Day 2 after the first omalizumab dose. Conclusion We identified several genes and miRNAs of interest, most of which have not been described to be linked to CSU so far, underlining, for example, to T cell involvement or even suggesting platelet involvement. |
| format | Article |
| id | doaj-art-e305a10c4c894cabbed874a533ae1a15 |
| institution | DOAJ |
| issn | 2050-4527 |
| language | English |
| publishDate | 2025-02-01 |
| publisher | Wiley |
| record_format | Article |
| series | Immunity, Inflammation and Disease |
| spelling | doaj-art-e305a10c4c894cabbed874a533ae1a152025-08-20T03:04:53ZengWileyImmunity, Inflammation and Disease2050-45272025-02-01132n/an/a10.1002/iid3.70132Omalizumab Treated Urticaria Patients Display T Cell and Thrombocyte‐Associated Gene RegulationAnna Smola0Heike C. Hawerkamp1Péter Oláh2Andreas Kislat3Nicole Duschner4Bernhard Homey5Stephan Meller6Department of Dermatology Medical Faculty Heinrich‐Heine‐University Duesseldorf GermanyDepartment of Dermatology Medical Faculty Heinrich‐Heine‐University Duesseldorf GermanyDepartment of Dermatology Medical Faculty Heinrich‐Heine‐University Duesseldorf GermanyDepartment of Dermatology Medical Faculty Heinrich‐Heine‐University Duesseldorf GermanyDepartment of Dermatology Medical Faculty Heinrich‐Heine‐University Duesseldorf GermanyDepartment of Dermatology Medical Faculty Heinrich‐Heine‐University Duesseldorf GermanyDepartment of Dermatology Medical Faculty Heinrich‐Heine‐University Duesseldorf GermanyABSTRACT Background Chronic spontaneous urticaria (CSU) is a debilitating inflammatory skin disease with a prevalence of approximately 1% of the population. It is characterized by recurrent itchy wheals and/or angioedema for more than 6 weeks without known triggers leading to a high quality of life impairment. The pathogenesis of CSU remains not fully understood. Objective This study aimed to explore the pathomechanism of CSU beyond mast cells and IgE‐dependent histamine release and to identify possible biomarkers for the disease and its treatment. Methods We investigated a patient cohort in the first month of omalizumab treatment regarding the IgE levels and changes in gene and miRNA expression in peripheral blood. The cohort was divided into responders and nonresponders (depending on the score of the urticaria control test) and compared to a group of healthy controls. Results Our messenger RNA and microRNA microarray analyses revealed the greatest changes in expression levels on Day 2 after the first omalizumab dose. Conclusion We identified several genes and miRNAs of interest, most of which have not been described to be linked to CSU so far, underlining, for example, to T cell involvement or even suggesting platelet involvement.https://doi.org/10.1002/iid3.70132 |
| spellingShingle | Anna Smola Heike C. Hawerkamp Péter Oláh Andreas Kislat Nicole Duschner Bernhard Homey Stephan Meller Omalizumab Treated Urticaria Patients Display T Cell and Thrombocyte‐Associated Gene Regulation Immunity, Inflammation and Disease |
| title | Omalizumab Treated Urticaria Patients Display T Cell and Thrombocyte‐Associated Gene Regulation |
| title_full | Omalizumab Treated Urticaria Patients Display T Cell and Thrombocyte‐Associated Gene Regulation |
| title_fullStr | Omalizumab Treated Urticaria Patients Display T Cell and Thrombocyte‐Associated Gene Regulation |
| title_full_unstemmed | Omalizumab Treated Urticaria Patients Display T Cell and Thrombocyte‐Associated Gene Regulation |
| title_short | Omalizumab Treated Urticaria Patients Display T Cell and Thrombocyte‐Associated Gene Regulation |
| title_sort | omalizumab treated urticaria patients display t cell and thrombocyte associated gene regulation |
| url | https://doi.org/10.1002/iid3.70132 |
| work_keys_str_mv | AT annasmola omalizumabtreatedurticariapatientsdisplaytcellandthrombocyteassociatedgeneregulation AT heikechawerkamp omalizumabtreatedurticariapatientsdisplaytcellandthrombocyteassociatedgeneregulation AT peterolah omalizumabtreatedurticariapatientsdisplaytcellandthrombocyteassociatedgeneregulation AT andreaskislat omalizumabtreatedurticariapatientsdisplaytcellandthrombocyteassociatedgeneregulation AT nicoleduschner omalizumabtreatedurticariapatientsdisplaytcellandthrombocyteassociatedgeneregulation AT bernhardhomey omalizumabtreatedurticariapatientsdisplaytcellandthrombocyteassociatedgeneregulation AT stephanmeller omalizumabtreatedurticariapatientsdisplaytcellandthrombocyteassociatedgeneregulation |